OpenLB
Open Library of Bioscience
Advanced Search
Frontiers in immunology
2023;14 1269391.

Targeting intracellular galectins for cancer treatment.

Rita Nehmé, Yves St-Pierre
Author Information
  1. Rita Nehmé: INRS-Centre Armand-Frappier Santé Biotechnologie, Laval, QC, Canada.
  2. Yves St-Pierre: INRS-Centre Armand-Frappier Santé Biotechnologie, Laval, QC, Canada.
PMID: 37753083 DOI: 10.3389/fimmu.2023.1269391

Abstract

Although considerable attention has been paid to the role of extracellular galectins in modulating, positively or negatively, tumor growth and metastasis, we have witnessed a growing interest in the role of intracellular galectins in response to their environment. This is not surprising as many galectins preferentially exist in cytosolic and nuclear compartments, which is consistent with the fact that they are exported outside the cells via a yet undefined non-classical mechanism. This review summarizes our most recent knowledge of their intracellular functions in cancer cells and provides some directions for future strategies to inhibit their role in cancer progression.

Keywords

cancer galectin inhibitors intrabodies intracellular nanobodies

References

  1. Sci Rep. 2017 Oct 16;7(1):13244 [PMID: 29038585]
  2. PLoS One. 2013 Jun 18;8(6):e65957 [PMID: 23824659]
  3. Biochim Biophys Acta Gen Subj. 2021 Jan;1865(1):129755 [PMID: 33011338]
  4. Acta Pharmacol Sin. 2017 Jun;38(6):806-822 [PMID: 28065935]
  5. Pharmacol Ther. 2020 Mar;207:107453 [PMID: 31836454]
  6. Biomaterials. 2021 Jan;268:120546 [PMID: 33253966]
  7. Elife. 2016 Jul 19;5: [PMID: 27434673]
  8. Biochemistry. 1999 Nov 16;38(46):15406 [PMID: 10563827]
  9. Nature. 1993 Jun 3;363(6428):446-8 [PMID: 8502296]
  10. Oncotarget. 2015 Dec 1;6(38):40970-80 [PMID: 26543238]
  11. Gut. 2002 Mar;50(3):392-401 [PMID: 11839721]
  12. Proc Natl Acad Sci U S A. 2016 Dec 27;113(52):14970-14975 [PMID: 27965386]
  13. Histol Histopathol. 2010 May;25(5):541-50 [PMID: 20238293]
  14. J Cancer. 2021 Mar 5;12(9):2654-2664 [PMID: 33854625]
  15. Oncotarget. 2017 Apr 11;8(15):25097-25106 [PMID: 28212576]
  16. J Biomed Sci. 2021 Mar 4;28(1):16 [PMID: 33663512]
  17. Oncogene. 2004 Sep 30;23(45):7527-36 [PMID: 15326483]
  18. Methods Mol Biol. 2015;1207:327-41 [PMID: 25253151]
  19. Gastric Cancer. 2023 May;26(3):352-363 [PMID: 36695981]
  20. Front Biosci (Landmark Ed). 2012 Jan 01;17(2):438-50 [PMID: 22201754]
  21. Front Immunol. 2017 Aug 18;8:1001 [PMID: 28868054]
  22. Sci Adv. 2022 Jul;8(26):eabl8247 [PMID: 35767614]
  23. PLoS One. 2013 Dec 10;8(12):e81883 [PMID: 24339976]
  24. J Pathol. 2009 Nov;219(3):347-55 [PMID: 19681071]
  25. J Invest Dermatol. 2012 Dec;132(12):2828-37 [PMID: 22785133]
  26. Front Immunol. 2023 Feb 03;14:1145268 [PMID: 36817445]
  27. PLoS One. 2015 Jul 13;10(7):e0131307 [PMID: 26168167]
  28. Open Biol. 2017 May;7(5): [PMID: 28490657]
  29. Nucleic Acids Res. 2001 Sep 1;29(17):3595-602 [PMID: 11522829]
  30. Mol Biol Cell. 2011 Apr;22(7):999-1013 [PMID: 21289092]
  31. Virol J. 2021 Apr 23;18(1):85 [PMID: 33892762]
  32. Eur J Med Chem. 2021 Mar 5;213:113050 [PMID: 33280896]
  33. J Am Heart Assoc. 2019 Oct 15;8(20):e012806 [PMID: 31594443]
  34. Biomaterials. 2022 Jul;286:121585 [PMID: 35623267]
  35. Nat Rev Drug Discov. 2012 Jun 29;11(7):519-25 [PMID: 22743979]
  36. Science. 2002 Mar 29;295(5564):2387-92 [PMID: 11923519]
  37. Mol Cell Biol. 2004 May;24(10):4395-406 [PMID: 15121858]
  38. Nat Rev Drug Discov. 2023 Apr;22(4):295-316 [PMID: 36759557]
  39. Nat Rev Clin Oncol. 2023 Apr;20(4):265-278 [PMID: 36781982]
  40. Arch Gynecol Obstet. 2022 Oct;306(4):1211-1220 [PMID: 35377045]
  41. Biochem Soc Trans. 2022 Feb 28;50(1):135-149 [PMID: 35015084]
  42. Autophagy. 2019 Jan;15(1):169-171 [PMID: 30081722]
  43. Pharmacol Ther. 2017 Jun;174:138-144 [PMID: 28223226]
  44. J Invest Dermatol. 2021 Mar;141(3):503-511.e9 [PMID: 32805218]
  45. Oncogene. 2001 Nov 8;20(51):7486-93 [PMID: 11709720]
  46. Tumour Biol. 2017 Mar;39(3):1010428317691687 [PMID: 28345468]
  47. J Gastroenterol. 2012 Jan;47(1):37-48 [PMID: 22015694]
  48. Cancers (Basel). 2020 Apr 12;12(4): [PMID: 32290551]
  49. Nat Rev Cancer. 2023 Aug;23(8):526-543 [PMID: 37311817]
  50. J Immunol. 2022 Jan 15;208(2):278-285 [PMID: 35017217]
  51. Am J Pathol. 2010 Jun;176(6):3023-31 [PMID: 20382700]
  52. Cancer Res. 2004 Sep 15;64(18):6363-7 [PMID: 15374939]
  53. Science. 2019 May 24;364(6442): [PMID: 31123109]
  54. Cancer Sci. 2014 Nov;105(11):1510-7 [PMID: 25230111]
  55. Structure. 1995 Dec 15;3(12):1379-93 [PMID: 8747464]
  56. Cell Syst. 2021 Jul 21;12(7):716-732.e7 [PMID: 34051140]
  57. Chembiochem. 2016 Sep 15;17(18):1759-70 [PMID: 27356186]
  58. Cells. 2019 Aug 27;8(9): [PMID: 31461880]
  59. Oncotarget. 2016 Apr 5;7(14):18183-203 [PMID: 26933916]
  60. Int J Cancer. 2011 Aug 15;129(4):799-809 [PMID: 21064109]
  61. Virchows Arch. 2017 Sep;471(3):375-382 [PMID: 28725929]
  62. Proc Natl Acad Sci U S A. 2018 Apr 17;115(16):E3769-E3778 [PMID: 29615514]
  63. Mol Cell. 2018 Apr 5;70(1):120-135.e8 [PMID: 29625033]
  64. Ann Rheum Dis. 2008 Feb;67(2):175-81 [PMID: 17545192]
  65. Nat Rev Cancer. 2006 Sep;6(9):729-34 [PMID: 16915295]
  66. Cells. 2023 Jan 29;12(3): [PMID: 36766779]
  67. Nat Methods. 2019 May;16(5):413-416 [PMID: 30962621]
  68. Int J Mol Sci. 2022 Jun 08;23(12): [PMID: 35742860]
  69. Inflamm Bowel Dis. 2008 Oct;14(10):1366-72 [PMID: 18484670]
  70. Glycobiology. 2013 May;23(5):508-23 [PMID: 23376190]
  71. Life Sci. 2021 Jul 15;277:119426 [PMID: 33785342]
  72. BMC Cancer. 2016 Jul 19;16:502 [PMID: 27435226]
  73. J Neurooncol. 2023 Mar;162(1):93-108 [PMID: 36854924]
  74. Semin Cancer Biol. 2014 Aug;27:30-8 [PMID: 24657939]
  75. Biomaterials. 2012 Mar;33(7):2260-71 [PMID: 22189143]
  76. J Biol Chem. 2004 Aug 13;279(33):34922-30 [PMID: 15205467]
  77. Nat Commun. 2020 Jun 26;11(1):3233 [PMID: 32591521]
  78. Cancer Res. 2007 Mar 15;67(6):2824-9 [PMID: 17363605]
  79. Cancer Res. 2016 Oct 1;76(19):5756-5767 [PMID: 27485450]
  80. J Allergy Clin Immunol. 2020 Aug;146(2):377-389.e10 [PMID: 31982451]
  81. Nat Commun. 2019 Sep 27;10(1):4403 [PMID: 31562305]
  82. Oncol Rep. 2014 Jul;32(1):23-32 [PMID: 24859692]
  83. Clin Exp Metastasis. 2013 Feb;30(2):119-32 [PMID: 22851004]
  84. Theranostics. 2018 Jun 13;8(14):3841-3855 [PMID: 30083263]
  85. Int J Clin Exp Pathol. 2017 Oct 01;10(10):10233-10242 [PMID: 31966357]
  86. Eur J Med Chem. 2021 Jul 5;219:113425 [PMID: 33862513]
  87. FASEB J. 2018 Jun 15;:fj201800687 [PMID: 29906246]
  88. Sci Rep. 2019 Feb 18;9(1):2186 [PMID: 30778105]
  89. Chem Biol. 2009 Jan 30;16(1):36-47 [PMID: 19171304]
  90. Protein Cell. 2016 May;7(5):314-24 [PMID: 27017379]
  91. Brain Pathol. 2010 Jan;20(1):39-49 [PMID: 18947333]
  92. Molecules. 2019 Mar 07;24(5): [PMID: 30866424]

MeSH Term

Cytosol
Galectins
Neoplasms

Chemicals

Galectins
Journal Article Review Research Support, Non-U.S. Gov't
Article has an altmetric score of 1

Word Cloud

Created with Highcharts 10.0.0galectinsintracellularcancerrolecellsAlthoughconsiderableattentionpaidextracellularmodulatingpositivelynegativelytumorgrowthmetastasiswitnessedgrowinginterestresponseenvironmentsurprisingmanypreferentiallyexistcytosolicnuclearcompartmentsconsistentfactexportedoutsideviayetundefinednon-classicalmechanismreviewsummarizesrecentknowledgefunctionsprovidesdirectionsfuturestrategiesinhibitprogressionTargetingtreatmentgalectininhibitorsintrabodiesnanobodies

Similar Articles

Cited By